论文部分内容阅读
目的观察阿卡波糖和阿卡波糖联合瑞格列奈治疗2型糖尿病的临床疗效及安全性。方法将48例2型糖尿病患者分2组,分别服用阿卡波糖和瑞格列奈联用阿卡波糖,疗程8周。检测治疗前后空腹(FBG)及餐后2h血糖(PBG)、糖化血红蛋白(HbAlc)、肝功、肾功。结果阿卡波糖组PBG治疗前后差异有统计学意义(P<0.05)。阿卡波糖联合瑞格列奈组FBG、PBG、HbAlc治疗前后差异有统计学意义(P<0.05)。无1例发生严重不良反应。结论阿卡波糖和瑞格列奈联合阿卡波糖治疗2型糖尿病降糖作用确切,而且安全性、耐受性良好。
Objective To observe the clinical efficacy and safety of acarbose and acarbose combined with repaglinide in the treatment of type 2 diabetes mellitus. Methods 48 patients with type 2 diabetes mellitus were divided into 2 groups, taking acarbose and repaglinide together with acarbose for 8 weeks. Fasting blood glucose (FBG) and 2h postprandial blood glucose (PBG), HbAlc, liver function and renal function were measured before and after treatment. Results Acarbose group PBG treatment before and after the difference was statistically significant (P <0.05). Acarbose combined with repaglinide group FBG, PBG, HbAlc treatment before and after the difference was statistically significant (P <0.05). No one case of serious adverse reactions. Conclusion Acarbose and repaglinide combined with acarbose treatment of type 2 diabetes hypoglycemic effect is exact, and good safety and tolerability.